Madrigal Pharmaceuticals (MDGL) Cash & Equivalents (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Cash & Equivalents data on file, last reported at $227.0 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 23.63% year-over-year to $227.0 million in Q1 2026; TTM through Mar 2026 was $227.0 million, a 23.63% increase from a year earlier, with the FY2025 full-year figure at $198.7 million, up 98.66% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $227.0 million, up from $198.7 million in the prior quarter.
• Over the last five years, Cash & Equivalents for MDGL reached as high as $622.5 million in Q1 2024 and fell as low as $42.3 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $198.8 million across 5 years, with a median of $183.6 million in 2025.
• Across the five-year window, Cash & Equivalents soared 814.14% in 2022 and plunged 70.5% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $331.5 million in 2022, then slumped by 69.86% to $99.9 million in 2023, then gained by 0.1% to $100.0 million in 2024, then jumped by 98.66% to $198.7 million in 2025, then gained by 14.26% to $227.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $227.0 million in Q1 2026, $198.7 million in Q4 2025, and $295.7 million in Q3 2025.